Jean Jacques Bienaime Biomarin Pharmaceutical Inc (BMRN) insider trading activity

Jean Jacques Bienaime is Director of BIOMARIN PHARMACEUTICAL INC. Currently has a direct ownership of 473,792 shares of BMRN, which is worth approximately $29.6 Million. The most recent transaction as insider was on Dec 21, 2023, when has been sold 10,000 shares (Common Stock) at a price of $63.1 per share, resulting in proceeds of $631,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 474K

0% 3M change

12.08% 12M change

Total Value Held $29.6 Million

JEAN JACQUES BIENAIME Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 21 2023	BUY Exercise of conversion of derivative security	$631,000 $63.1 p/Share	10,000 Added 2.25%	435,112 Common Stock
Dec 01 2023	BUY Grant, award, or other acquisition	-	2,370 Added 0.55%	425,112 Common Stock
Oct 04 2023	BUY Small Acquisition	$855 $85.57 p/Share	10 Added 0.0%	422,742 Common Stock
Aug 08 2023	SELL Open market or private sale	$529,740 $88.29 p/Share	6,000 Reduced 1.4%	422,732 Common Stock
Aug 07 2023	SELL Open market or private sale	$352,400 $88.1 p/Share	4,000 Reduced 0.92%	428,732 Common Stock
May 12 2023	SELL Payment of exercise price or tax liability	$3,755,415 $93.93 p/Share	39,981 Reduced 8.46%	432,732 Common Stock
May 12 2023	BUY Exercise of conversion of derivative security	$3,153,165 $67.81 p/Share	46,500 Added 8.96%	472,713 Common Stock
May 11 2023	SELL Open market or private sale	$2,846,700 $94.89 p/Share	30,000 Reduced 6.58%	426,213 Common Stock
May 11 2023	BUY Exercise of conversion of derivative security	$2,034,300 $67.81 p/Share	30,000 Added 6.17%	456,213 Common Stock
May 10 2023	SELL Open market or private sale	$2,849,700 $94.99 p/Share	30,000 Reduced 6.58%	426,213 Common Stock
May 10 2023	BUY Exercise of conversion of derivative security	$2,034,300 $67.81 p/Share	30,000 Added 6.17%	456,213 Common Stock
May 09 2023	SELL Open market or private sale	$2,856,000 $95.2 p/Share	30,000 Reduced 6.58%	426,213 Common Stock
May 09 2023	BUY Exercise of conversion of derivative security	$2,034,300 $67.81 p/Share	30,000 Added 6.17%	456,213 Common Stock
Apr 28 2023	BUY Grant, award, or other acquisition	$21,200 $66.88 p/Share	317 Added 0.07%	426,213 Common Stock
Apr 10 2023	SELL Open market or private sale	$995,600 $99.56 p/Share	10,000 Reduced 2.29%	425,896 Common Stock
Apr 10 2023	BUY Exercise of conversion of derivative security	$678,100 $67.81 p/Share	10,000 Added 2.24%	435,896 Common Stock
Apr 06 2023	SELL Open market or private sale	$961,300 $96.13 p/Share	10,000 Reduced 2.29%	425,896 Common Stock
Apr 06 2023	BUY Exercise of conversion of derivative security	$678,100 $67.81 p/Share	10,000 Added 2.24%	435,896 Common Stock
Mar 16 2023	SELL Payment of exercise price or tax liability	$8,278,274 $93.41 p/Share	88,623 Reduced 17.22%	425,896 Common Stock
Mar 15 2023	SELL Payment of exercise price or tax liability	$828,002 $87.74 p/Share	9,437 Reduced 1.8%	514,519 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	36,100 Added 6.45%	523,956 Common Stock
Mar 13 2023	SELL Open market or private sale	$723,600 $90.45 p/Share	8,000 Reduced 1.61%	487,856 Common Stock
Mar 13 2023	BUY Exercise of conversion of derivative security	$542,480 $67.81 p/Share	8,000 Added 1.59%	495,856 Common Stock
Mar 10 2023	SELL Open market or private sale	$1,384,200 $92.28 p/Share	15,000 Reduced 2.98%	487,856 Common Stock
Mar 10 2023	BUY Exercise of conversion of derivative security	$1,017,150 $67.81 p/Share	15,000 Added 2.9%	502,856 Common Stock

Also insider at

INCY

INCYTE CORP Healthcare

Director

IMNM

Immunome Inc. Healthcare

KROS

Keros Therapeutics, Inc. Healthcare

JJB